Loading company…
Moleculent develops technology to measure cell interactions and support functional proteomics research.
Founded in 2021 in Solna, Sweden, Moleculent develops technology for studying cell interactions and disease mechanisms in tissue. Its platform measures cell-to-cell interactions and supports functional proteomics research. In April 2026, the company raised USD 20 million in Series A funding led by Rubicon Healthcare Partners, with ARCH Venture Partners and Eir Ventures participating. The funding will support its early access program, US commercial operations and an automated instrument launch.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in